Abstract
Objectives: The objective of the current review was to assess published data on the role of Positron Emission Tomography (PET) for evaluation of nodal residual disease after definitive chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Studies were identified by searching PubMed electronic databases. Only studies using a post-chemoradiotherapy PET for nodal residual disease evaluation were included in the present review. Both prospective and retrospective studies were included. Information regarding sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET for detecting nodal residual disease after definitive chemoradiotherapy for HNSCC was extracted and analyzed. Results: Twenty published studies were included in the present review. Existing data suggest that a negative postchemoradiotherapy PET scan is associated with a negative predictive value up to 100%. The sensitivity of PET in detecting nodal residual disease is greater for scans performed ≥ 10 weeks after definitive treatment with chemoradiotherapy for HNSCC. Conclusions: Further studies are needed to quantify the reliability of PET in detecting nodal residual disease after chemoradiotherapy for locoregionally advanced HNSCC. The optimal timing of PET imaging after chemoradiotherapy remains to be defined.
Keywords: Positron Emission Tomography, Neck Dissection, Head Cancer, Neck Cancer, cell carcinoma, cervical nodal disease, CT scan, hypermetabolic areas, omography, Papillomavirus, Head and Neck Cancer
Reviews on Recent Clinical Trials
Title: Positron Emission Tomography for Neck Evaluation Following Definitive Treatment with Chemoradiotherapy for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Volume: 7 Issue: 1
Author(s): Voichita Bar-Ad, Mark Mishra, Nitin Ohri and Charles Intenzo
Affiliation:
Keywords: Positron Emission Tomography, Neck Dissection, Head Cancer, Neck Cancer, cell carcinoma, cervical nodal disease, CT scan, hypermetabolic areas, omography, Papillomavirus, Head and Neck Cancer
Abstract: Objectives: The objective of the current review was to assess published data on the role of Positron Emission Tomography (PET) for evaluation of nodal residual disease after definitive chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Studies were identified by searching PubMed electronic databases. Only studies using a post-chemoradiotherapy PET for nodal residual disease evaluation were included in the present review. Both prospective and retrospective studies were included. Information regarding sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET for detecting nodal residual disease after definitive chemoradiotherapy for HNSCC was extracted and analyzed. Results: Twenty published studies were included in the present review. Existing data suggest that a negative postchemoradiotherapy PET scan is associated with a negative predictive value up to 100%. The sensitivity of PET in detecting nodal residual disease is greater for scans performed ≥ 10 weeks after definitive treatment with chemoradiotherapy for HNSCC. Conclusions: Further studies are needed to quantify the reliability of PET in detecting nodal residual disease after chemoradiotherapy for locoregionally advanced HNSCC. The optimal timing of PET imaging after chemoradiotherapy remains to be defined.
Export Options
About this article
Cite this article as:
Bar-Ad Voichita, Mishra Mark, Ohri Nitin and Intenzo Charles, Positron Emission Tomography for Neck Evaluation Following Definitive Treatment with Chemoradiotherapy for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma, Reviews on Recent Clinical Trials 2012; 7(1) . https://dx.doi.org/10.2174/157488712799363226
DOI https://dx.doi.org/10.2174/157488712799363226 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen
Current Signal Transduction Therapy A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry Traditional Chinese Medicines (TCMs) for Molecular Targeted Therapies of Tumours
Current Drug Discovery Technologies MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews Impact of microRNAs in Resistance to Chemotherapy and Novel Targeted Agents in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect
Current Gene Therapy The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1)
Anti-Cancer Agents in Medicinal Chemistry Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Current Drug Targets Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Current Pharmaceutical Design Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2)
Current Cancer Drug Targets Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Formulation Considerations of Gadolinium Lipid Nanoemulsion for Intravenous Delivery to Tumors in Neutron-Capture Therapy
Current Drug Delivery The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Epidermal Growth Factor Receptor and its Trafficking Regulation by Acetylation: Implication in Resistance and Exploring the Newer Therapeutic Avenues in Cancer
Current Topics in Medicinal Chemistry